Repligen Corporation (RGEN): Price and Financial Metrics
GET POWR RATINGS... FREE!
RGEN POWR Grades
- RGEN scores best on the Growth dimension, with a Growth rank ahead of 83.13% of US stocks.
- RGEN's strongest trending metric is Sentiment; it's been moving down over the last 179 days.
- RGEN's current lowest rank is in the Momentum metric (where it is better than 8.94% of US stocks).
RGEN Stock Summary
- RGEN's current price/earnings ratio is 57.29, which is higher than 90.26% of US stocks with positive earnings.
- Price to trailing twelve month operating cash flow for RGEN is currently 59.63, higher than 92.85% of US stocks with positive operating cash flow.
- With a price/sales ratio of 11.89, REPLIGEN CORP has a higher such ratio than 91.04% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to REPLIGEN CORP, a group of peers worth examining would be OMCL, TECH, STAA, SLP, and ZIP.
- RGEN's SEC filings can be seen here. And to visit REPLIGEN CORP's official web site, go to www.repligen.com.
RGEN Valuation Summary
- RGEN's EV/EBIT ratio is 45.7; this is 431.4% higher than that of the median Healthcare stock.
- Over the past 243 months, RGEN's EV/EBIT ratio has gone up 64.2.
Below are key valuation metrics over time for RGEN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RGEN | 2022-11-25 | 11.9 | 5.2 | 57.3 | 45.7 |
| RGEN | 2022-11-23 | 12.0 | 5.2 | 57.6 | 46.0 |
| RGEN | 2022-11-22 | 11.9 | 5.2 | 57.4 | 45.8 |
| RGEN | 2022-11-21 | 12.1 | 5.3 | 58.1 | 46.3 |
| RGEN | 2022-11-18 | 12.2 | 5.3 | 58.7 | 46.9 |
| RGEN | 2022-11-17 | 12.1 | 5.3 | 58.3 | 46.5 |
RGEN Growth Metrics
- Its 2 year net cashflow from operations growth rate is now at 98.43%.
- Its 3 year price growth rate is now at 125.47%.
- Its year over year price growth rate is now at -19.09%.
The table below shows RGEN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 801.295 | 159.821 | 166.34 |
| 2022-06-30 | 778.77 | 140.937 | 159.433 |
| 2022-03-31 | 734.097 | 132.867 | 145.805 |
| 2021-12-31 | 670.534 | 119.016 | 128.291 |
| 2021-09-30 | 592.661 | 84.267 | 118.879 |
| 2021-06-30 | 508.505 | 83.273 | 99.933 |
RGEN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RGEN has a Quality Grade of C, ranking ahead of 39.46% of graded US stocks.
- RGEN's asset turnover comes in at 0.293 -- ranking 157th of 682 Pharmaceutical Products stocks.
- ORMP, MESO, and AWH are the stocks whose asset turnover ratios are most correlated with RGEN.
The table below shows RGEN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.293 | 0.586 | 0.452 |
| 2021-06-30 | 0.278 | 0.588 | 0.369 |
| 2021-03-31 | 0.257 | 0.574 | 0.269 |
| 2020-12-31 | 0.235 | 0.572 | 0.186 |
| 2020-09-30 | 0.229 | 0.576 | 0.144 |
| 2020-06-30 | 0.215 | 0.569 | 0.109 |
RGEN Price Target
For more insight on analysts targets of RGEN, see our RGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $267.88 | Average Broker Recommendation | 1.35 (Strong Buy) |
RGEN Stock Price Chart Interactive Chart >
RGEN Price/Volume Stats
| Current price | $186.05 | 52-week high | $274.09 |
| Prev. close | $188.17 | 52-week low | $137.21 |
| Day low | $180.11 | Volume | 389,505 |
| Day high | $189.58 | Avg. volume | 546,327 |
| 50-day MA | $186.38 | Dividend yield | N/A |
| 200-day MA | $184.70 | Market Cap | 10.33B |
Repligen Corporation (RGEN) Company Bio
Repligen Corporation develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company was founded in 1981 and is based in Waltham, Massachusetts.
Latest RGEN News From Around the Web
Below are the latest news stories about REPLIGEN CORP that investors may wish to consider to help them evaluate RGEN as an investment opportunity.
BIIB or RGEN: Which Is the Better Value Stock Right Now?BIIB vs. RGEN: Which Stock Is the Better Value Option? |
Declining Stock and Decent Financials: Is The Market Wrong About Repligen Corporation (NASDAQ:RGEN)?It is hard to get excited after looking at Repligen's (NASDAQ:RGEN) recent performance, when its stock has declined 22... |
Repligen Corporation to Present at Upcoming Investor ConferencesWALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at two upcoming investor conferences. The Stifel 2022 Healthcare Conference being held November 15-16 in New York. Jon K. Snodgres, Chief Financial Officer, will participate in an analyst-led discussion on Wednesday, November 16, at 2:25 p.m. EST.Stephens’ Annual Investment Conference being held November |
BIIB vs. RGEN: Which Stock Is the Better Value Option?BIIB vs. RGEN: Which Stock Is the Better Value Option? |
A Look At The Fair Value Of Repligen Corporation (NASDAQ:RGEN)In this article we are going to estimate the intrinsic value of Repligen Corporation ( NASDAQ:RGEN ) by taking the... |
RGEN Price Returns
| 1-mo | 8.47% |
| 3-mo | -11.55% |
| 6-mo | 12.63% |
| 1-year | -30.79% |
| 3-year | 111.93% |
| 5-year | 423.94% |
| YTD | -29.75% |
| 2021 | 38.20% |
| 2020 | 107.17% |
| 2019 | 75.39% |
| 2018 | 45.37% |
| 2017 | 17.72% |
Continue Researching RGEN
Want to see what other sources are saying about Repligen Corp's financials and stock price? Try the links below:Repligen Corp (RGEN) Stock Price | Nasdaq
Repligen Corp (RGEN) Stock Quote, History and News - Yahoo Finance
Repligen Corp (RGEN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...